Aricept (donepezil) slows the breakdown of acetylcholine, a chemical involved in memory and cognition. It can modestly ease Alzheimer's symptoms, but it does not cure the disease, stop eventual decline, or treat every form of dementia.
Aricept is an acetylcholinesterase inhibitor. The U.S. FDA label on DailyMed indicates it for mild, moderate, and severe dementia of the Alzheimer's type—not dementia broadly.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Aricept change in the brain?
- How much improvement should families expect?
- Does the dementia diagnosis matter?
- How is Aricept started and increased?
- Side effects and warning signs
What does Aricept change in the brain?
brain cells use acetylcholine to send signals involved in memory and thinking. Acetylcholinesterase is an enzyme that breaks down this chemical after it has carried a signal. Donepezil reversibly blocks that enzyme.
As a result, acetylcholine remains available longer, increasing communication through the brain's cholinergic signaling system. This mechanism can support remaining brain function, but it does not repair damaged cells or address the underlying dementing process. Symptoms may still worsen as Alzheimer's progresses.
How much improvement should families expect?
benefits are usually modest and vary from person to person. In controlled trials, donepezil performed better than placebo on measures of cognition and overall or functional ability. In one six-month trial involving 248 people with severe Alzheimer's, the average difference on the Severe Impairment Battery favored donepezil by 5.9 points.
This shows a measurable group-level benefit, not a return to previous functioning for every participant. A 2018 Cochrane review found small average improvements in cognition, daily activities, and clinician-rated overall condition over 12 to 24 weeks. For an individual, benefit may mean maintaining an ability longer or declining more slowly during the treatment period rather than showing an obvious improvement.
Does the dementia diagnosis matter?
Yes. "Dementia" describes a syndrome with several possible causes, and Aricept does not have the same role in each one. A clear diagnosis helps families weigh likely benefit against medication risks. The U.S.
indication covers dementia of the Alzheimer's type. Outside that indication, guidance depends on the condition: NICE recommends donepezil for dementia with Lewy bodies, limits cholinesterase inhibitors in vascular dementia to suspected mixed disease, and advises against them for frontotemporal dementia. Someone described only as having "dementia" should therefore ask which type is suspected. This is especially important when symptoms or test results suggest more than one disease process.
How is Aricept started and increased?
U.S. labeling starts most patients at 5 mg once daily. The dose may rise to 10 mg only after four to six weeks, while 23 mg is reserved for patients who have taken 10 mg for at least three months.
Gradual increases reduce cholinergic side effects. A proposed increase should account for current benefit, existing nausea or appetite loss, heart-conduction problems, fainting, and fall risk. Useful questions for the prescribing visit include:.
- What specific ability or symptom are we hoping to support?
- When will benefit and side effects be reviewed?
- What would justify remaining at the current dose?
- Which symptoms should prompt a call before the next appointment?
Side effects and warning signs
Common effects include nausea, diarrhea, vomiting, appetite loss, insomnia, muscle cramps, and fatigue. Donepezil can also slow the heart rate or contribute to heart block and fainting, making these risks especially important for people with conduction disease or a high fall risk. The 23-mg dose has a greater tolerability burden. In a controlled trial reported in the U.S.
FDA label on DailyMed, nausea occurred in 11.8% of patients taking 23 mg versus 3.4% taking 10 mg; vomiting occurred in 9.2% versus 2.5%. Treatment discontinuation because of adverse events was 18.6% versus 7.9%. Caregivers can record appetite, digestive symptoms, sleep, energy, falls, fainting, and day-to-day functioning after treatment begins or the dose changes. Report fainting or signs of an unusually slow heartbeat promptly rather than waiting for a routine review.
